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High-throughputWe have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types
associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11),
or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of antibodies in 546 patients, which
had either cervical carcinomas, or precursor lesions, or which were asymptomatic. All patient groups
contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity.
Computational analyses showed the E7 proteins of carcinogenic HPV types as signiﬁcantly more reactive in
cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL
patients. Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential
reactivity relative to pathology. Our study introduces a new approach to future evaluation of the overall
antigenicity of HPV proteins and cross-reaction between homologous proteins.r Biology and Biochemistry,
x: +1 949 824 8551.
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Human papillomaviruses (HPVs) infect the skin and anogenital
and oropharyngeal mucosal epithelia. More than 100 HPV types have
been described (Bernard et al., 2010), and each of these viruses shows
type-speciﬁc tropism for cutaneous or mucosal epithelia as well as
type-speciﬁc histological characteristics of the lesion. Many HPV
infections are subclinical, while other infections become clinically
apparent in the form of benign neoplastic growth. A subset of lesions,
associated normally with so-called “high-risk” HPV types (Munoz et
al., 2003), evolve into malignancies. This causal association between
high-risk HPV types and anogenital cancers, most notably cancer of
the cervix uteri, has attracted by far the largest share of research
activities in HPV biology and pathogenesis (zur Hausen, 2002).
Research of humoral immune responses against HPV proteins is
highly developed (Egelkrout and Galloway, 2007; Reuschenbach et al.,2008), but its success differs between different research specialties.
On the one side, assembly of virus-like particles based on the capsid L1
protein has led to the introduction of anti-HPV vaccines, whose
success is based on stimulating an anti-L1 humoral immune response
and immunoglobulin G secretion into the cervical mucus at concen-
trations exceeding those measured in response to natural infections
(Villa et al., 2006). On the other hand, independent serological studies
of natural HPV infections have not led to the development of a
serology-based diagnosis of HPV infections or the use of serology as a
predictive marker of HPV disease progression. Many discrepancies
that were encountered by this research are still poorly understood.
For example, some cervical cancer patients, although expressing the
oncoproteins E6 and E7 throughout the tumor, do not show immune
responses against these proteins, although increases of immune
reactivity with disease progression have been observed (Lehtinen et
al., 2003; Meschede et al., 1998; Reuschenbach et al., 2008; Stanley,
2003). Patients without detectable HPV-associated lesions, but
diagnosed as being infected with speciﬁc HPV types by DNA testing,
often lack serological responses against the incident infection (Rosales
et al., 2001). And patients with documented serological responses
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infections, particularly in the case of HPV types speciﬁc for the skin
(Steger et al., 1990; Waterboer et al., 2009). One may suspect that
some of these discrepancies stem from histological idiosyncrasies of
HPV infections. Regulatory HPV proteins as well as viral particles are
expressed in suprabasal layers of squamous epithelia and subse-
quently shed at mucosal or cutaneous surfaces rather than spread
systemically as the viral gene products in many other virus infections.
On the other side, the serological literature also suffers from technical
limitations, as most studies targeted single or few HPV proteins of one
or few HPV types, and there are no studies yet that measured the
immune responses against all eight proteins of a single HPV type or
even of numerous HPV types.
We describe here a high-throughput approach that allows examin-
ing the sera of hundreds of patients for reactivity against all eight
proteins encodedby a large number of differentHPV types. In this study,
we examined the humoral immune response against the proteomes of
13 of the most common HPV types associated with cervical cancer,
genital and laryngeal warts, common warts, and epidermodysplasia
verruciformis. The approach is based on PCR ampliﬁcation of genes, in
vivo recombination cloning and in vitro expression of these proteins,
and printing onto microarray chips. This technology has been used to
characterize the humoral immune response proﬁle qualitatively and
quantitatively in tiny amounts of serum in studies of the proteomes of
large DNA viruses, bacteria, and protozoa (Barbour et al., 2008; Beare et
al., 2008; Davies et al., 2008; Doolan et al., 2008). Our project aimed to
generate global insight into the humoral immune response against HPV
proteins and asked the particular question of whether a comparison of
the seroresponses against all proteins of numerous HPV types would
reveal preferential immune reactions in relationship to pathology, e.g.,
toprogressionof anogenital cancer.Wearepresenting selecteddata sets
generated with a technological platform that offers broad approaches
for future research as it overcomes restriction to only small sets of HPV
proteins and HPV types.Fig. 1. Representative example of the raw data generated by processing HPV protein microar
duplicates of 104 HPV proteins and additional controls. Brightness of spots correlates with
contains all positive controls. This particular microarray has been probed with serum from a
eight HPV types. The uppermost line includes human IgGs and EBNA1 protein as controls.Results
Overall strategy
All previously published investigations of humoral immune
responses against HPV proteins addressed individual proteins or
small sets of proteins of one or few HPV types, respectively. We
undertook the research reported here to simultaneously evaluate
serological responses against the proteins derived from all eight open
reading frames from a set of themost common andmost often studied
HPV types. For this purpose, we selected sevenHPV types of the alpha-
PV genus that are considered carcinogenic and frequently found in
cervical cancer (HPV-16, -18, -31, -33, -35, -45, and -53), two HPV
types, also of the alpha-PV genus, which are the cause of genital and
laryngeal warts (HPV-6 and -11), and one more alpha HPV type, HPV-
2, that causes common warts. We also included three additional HPV
types found in cutaneous lesions and that belong to three unrelated
genera, namely, HPV-1, -4, and -5 (de Villiers et al., 2004).
The laboratory of one of us (P.L.F.) has developed a strategy to
clone all open reading frames of any organism into a phage-T7
promoter-based Escherichia coli vector by homologous recombination,
followed by expression of the whole proteome of the organism by in
vitro transcription and translation. Aliquots of each protein are
printed on slides in a microarray format for quantitative serological
evaluation of patient sera using ﬂuorescent anti-human secondary IgG
antibodies (Barbour et al., 2008; Beare et al., 2008; Davies et al., 2005a,
b, 2008). For this, a restriction linearized and PCR ampliﬁed T7
expression vector, pXi, was used encoding an N-terminal His- and a C-
terminal HA tag spanning the cloning site. We inserted all eight genes
from the genomes of the 13 HPV types into this vector with gene-
speciﬁc primers containing 20 nucleotide extensions complementary
to HPV gene sequences and 33 nucleotide extensions complementary
to the ends of the linear T7 vector. The two components were linked in
vivo by transformation ofmixtures of HPV genes and linear vector intorays with a patient serum. The ﬁgure shows a slide with 16microarrays, each containing
increased seroreactivity. The upper line of white spots indicating maximal reactivity
cervical cancer patient. The strongest reactions, indicated, are 15 different proteins from
Fig. 2. Complex multitarget as well as low serological activity in patients with HPV-associated cancers, in HPV-infected asymptomatic patients, and in HPV-negative patients.
Documentation of the diversity of individual data that led to the heat map in Fig. 3 and the analyses in Figs. 4 and 5. This ﬁgure represents the only data in this article that compare
HPV-positive and HPV-negative asymptomatic patients, as analyses not discussed here did not reveal obvious serological differences between the two groups.
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expression vectors for all 104 HPV proteins. Recombinants were
grown under antibiotic resistance without colony selection and
minipreparations of each were sequenced in order to conﬁrm the
expected presence of the HPV genes. HPV proteins were expressed by
in vitro transcription and translation in an E. coli-based cell-free
system and spotted in a microarray format. Expression of all cloned
proteins was conﬁrmed by reaction with anti-His and anti-HA
antibodies. Fig. 1 shows the data output and demonstrates a typical
slide with 16 microarrays, each containing duplicates of 104 HPV
proteins and additional controls.Fig. 3. Heat map of 113,568 microarray signals generated by 546 sera targeted at all 104 pr
strong (red), moderate (black) to weak (green). Columns correlate to samples sorted by subj
patients with cervical cancer, HSIL, LSIL, and asymptomatic infection.Validation of the microarray with anti-HPV monoclonal antibodies
As initial validation of the array, we investigated whether
commercial monoclonal antibodies raised against speciﬁc proteins
of various HPV types would detect the homologous target protein. We
also looked for cross-reactivity with homologous proteins of other
HPV types and nonspeciﬁc cross-reactivity with heterologous pro-
teins. Altogether, we analyzed 12 different monoclonal antibodies,
which are listed in the Materials and methods section. Fig. S1A shows
the reaction of an anti-HPV-16 E7 antibody against HPV-16 E7 and
cross-reaction with the E7 proteins of HPV-31, -33, and -35, the threeoteins encoded by 13 HPV types. A color scale identiﬁes signal intensities ranging from
ects, lines correlate to the different proteins. The whole collection of sera is grouped into
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S1B shows a similar example, the reaction of an anti-HPV-11 E7
antibody with the HPV-11 E7 protein. There is cross-reaction with the
E7 protein of HPV-6, the closest relative of HPV-11, and with the
remotely related HPV-16 and HPV-31 E7 proteins. Fig. S1C shows an
example of strict speciﬁcity. An anti-HPV-16 E1/E4 antibody correctly
recognizes the HPV-16 E4 protein, and no other protein. A very
complex outcome is shown in Fig. S1D. An anti-HPV-16 L1monoclonal
antibody recognizes the HPV-16 L1 protein and the homologous L1
proteins of HPV-1, -2, -6, -11, -18, -31, -33, and -53. In contrast, HPV-4
and -5 L1 were not recognized by this antibody, although controls
showed high expression of the HPV-4 and -5 L1 proteins. The possible
cross-reaction with HPV-45 L1 could not be examined, as this protein
was not present on this particular chip. Surprisingly, this antibody also
shows that our test system is occasionally not sufﬁciently speciﬁc, as
there was nonspeciﬁc cross-reactivity with the E1 proteins of HPV-31,
-35, and -53, and the L2 protein of HPV-18 despite the lack of
sequence homologies. The arrays also contained HPV-16 virus like
particles obtained from an anti-HPV-16 vaccine. This positive control
was included since HPV-16 L1 gave in this experiment a weaker signal
with the anti-HPV-16 L1 monoclonal than with the L1 proteins of
some related HPV types either due to suboptimal folding or
suboptimal expression of HPV-16 L1. A quantitative comparison of
signal intensities between these two L1 proteins may not be reliable
due to the nonuniform amount of proteins spotted in this type of
array.
The other eight monoclonal antibodies showed speciﬁc reactivity
with the appropriate target, and no cross-reactivity with homologous
proteins of other HPV types or nonspeciﬁc reactions with heterolo-
gous proteins was observed (data not shown).
Low, or lack of, anti-HPV protein reactivity of sera from children without
known exposure to sexually transmitted HPV types
Since studies by others as cited above have found extensive anti-
HPV immunoreactivity of sera of adult and sexually active individuals,
we chose to include a negative control in our study and analyzed the
sera of 10 children aged 2–3 years who were presumed not to have
been exposed to sexually transmitted HPV types (Fig. S2). Eight of
these children, represented by the individuals K27 and K39, showed
no anti-HPV protein reactivity whatsoever. Individual K73 had
antibodies against HPV-5 L2, and K66 antibodies against HPV-35 E4
and E5. These sera, whichwere obtained from a region of Africa (Mali)
with endemic malaria, showed strong reactivity to antigens from
Plasmodium falciparum (Doolan et al., 2008), indicating that these sera
were in good condition. However, we are cognizant that immuno-
suppression, often associated with malaria, may inﬂuence the
antibody proﬁle. With this caveat in mind, we conclude that the
sera sampled from children before puberty in most cases do not show
extensive reactivity against HPV proteins.
Complex multitarget serological reactivity in patients with
HPV-associated cancers, in HPV-infected asymptomatic patients, and in
HPV-negative patients
We asked whether our approach may conﬁrm observations by
others (deGruijl et al., 1997;Meschede et al., 1998; Ravaggi et al., 2006)
that patients may have strong reactivity against HPV proteins only if
they are afﬂictedwithHPV-associatedneoplasia and that themajority of
healthy subjects without cervical cancer would be seronegative. Fig. 2Fig. 4. Comparison of the seroreactivity of HPV proteins in cancer and asymptomatic patients
healthy subjects (blue bars) and 93 cervical cancer patients (red bars), and the p-value (black
less than 0.05 are considered signiﬁcant (below the red horizontal line). (A) The antigens we
differentially reactive antigens (left) and 43 cross-reactive antigens (p value N0.05, right). Pr
antigens were organized according to annotated gene ID. All HPV proteins are shown. One tshows examples that visualize the raw data obtained with six patient
sera that represent the range of responses throughout thewhole group.
Surprisingly, our results show that independent of disease status,
subjects may or may not have strong reactivity against HPV proteins.
Patients with an HPV-16 cervical carcinoma can have extensive
reactivity against HPV proteins (with 4 of 21 signals derived from
HPV-16 E1, E2, E4, and E7) as shown in Fig. 2A, or nearly no reactivity as
shown in Fig. 2B. Patientswith anHPV-16-positive smear can have anti-
HPV reactivity as shown in Fig. 2C, while otherswith this diagnosis may
lack such antibodies (Fig. 2D). Patients without present HPV infections
may show extensive or no anti-HPV protein reactivity (Figs. 2E and F,
respectively). The six panels of Fig. 2 document individual data, but a
representation of all 113,568 data points (duplicates of 104 HPV
proteins targeted by 546 sera) requires a heat map.
Heat maps of the reaction of 546 sera with the eight proteins of 13 HPV
types
Fig. 3 shows all data of this study in the form of a heat map, the 546
sera aligned along the x-axis, and the 104 HPV proteins along the y-
axis. This particular alignment presents all data after sorting the
samples into cancer patients, or individuals with HSIL, LSIL, or
asymptomatic infection. Mere inspection of this crude and unedited
presentation of the raw data of our study does not reveal obvious
differences between these groupings of patients.
Seroreactivity in correlation with disease state or HPV infection
Fig. 4 shows one approach to edit the data of Fig. 3. Here, we have
used T-tests to identify differentially reactive antigens between two
different patient groups. In Fig. 4A, the data are organized showing 16
signiﬁcantly differentially reactive antigens (14 of these early
proteins) (left) and 43 cross-reactive antigens (right). Red and blue
bars are based on the reactivity of sera from cancer patients (93
individuals) and asymptomatic subjects (280 individuals), respective-
ly. The p-values comparing the two groups are plotted in the upper
part of the ﬁgures as a dark black line, whose exponential scale is
indicated along the right margin of the ﬁgure. The threshold for
signiﬁcance was set at 0.05 (light red line). It is apparent that the p
values of all antigens on the left side of Fig. 4A are smaller than this
threshold and that the ﬁve proteins with the highest differential
reactivity of all 104 proteins include four E7 proteins of cancer-
associated HPV types, namely those of HPV-16, -31, -18, and -33, with
E7 of HPV-35 following in ninth position. In Fig. 6B, the data are
organized according to the genetic identity of the antigen. The most
signiﬁcantly differentially reactive antigens are the E7 proteins,
followed by E1 and E4. Fig. 4B also gives an impression of the overall
seroreactivity of all proteins, which, however, could not be precisely
quantiﬁed, since the exact quantity of each protein spotted in the
microarray was not constant. It is apparent, however, that E5, E4, and
E7 were the most highly reactive proteins, while E6 showed least
reactivity. The dichotomy between the reactivity of the two oncopro-
teins is not surprising, as it is generally recognized that E6 is only
marginally detectable in cancer and cancer cell lines, while E7 is highly
expressed in all lesions (McLaughlin-Drubin and Münger, 2009).
The 14 E antigens that are differentially reactive between cancer
patients and asymptomatic subjects are further analyzed in Fig. 5A.
HPV-31 E7 and HPV-18 E7 are the most signiﬁcant differentially
reactive antigens with p values b1E−6. Differential reactivity is still
evident between cancer patients and HSIL subjects although with. Themean and standard error of each antigen on themicroarraywas determined for 280
line) comparing the two groupswas determined.Multiple comparison corrected p values
re sorted by decreasing average signal intensity and organized to show 16 signiﬁcantly
oteins with average signal intensity lower than no DNA controls are not shown. (B) The
hird of the signiﬁcant proteins (pb0.05) are E7 proteins.
Fig. 5. Differential seroreactivity against HPVs early proteins. (A) The differentially
reactive E antigens comparing 280 subjects without lesions and 93 cervical cancer
patients. (B) The same antigens were plotted comparing 93 cancer patients with 50
HSIL patients. (C) The same antigens were plotted comparing 280 subjects without
lesions with 50 HSIL patients. Multiple comparison corrected p values less than 0.05 are
considered signiﬁcant (signal extending below the red horizontal line).
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difference in reactivity of these antigens between HSIL patients and
asymptomatic subjects (Fig. 5C). All individual p values for the
comparison of 14 E proteins among all groups of subjects are listed in
Table 1.
As the E7 protein is consistently and strongly expressed in cervical
carcinomas, we asked whether in cancer patients with known HPV
DNA diagnosis, there are consistent serological responses against the
homologous E7 proteins. As shown in Fig. 6, there was an anti-E7
response in 44 (63%), 3 (33%), and 1 serum (13%) of 70, nine and eight
patients afﬂicted with HPV-16, -18, and -31 tumors, respectively. As a
group cervical cancer patients react preferentially to E7 antigens,
some cancer patients fail to react.
We also askedwhether it is possible thatmany signals evaluated in
this study do not reﬂect HPV type speciﬁc seroreactivity but rather
cross-reactivity with homologous proteins of related HPV types, as
suggested by the cross-reactivity of monoclonal antibodies that had
been raised against HPV type speciﬁc E7 and L1 proteins (Fig. S1). A
precise evaluation of this possibility would only be possible if one
would observe frequently simple patterns of seroreactivity against
single HPV proteins, which unfortunately were very rarely encoun-
tered. To get an estimate whether cross-reactivities created a major
bias in this study, we asked how frequently one obtains reactions with
multiple homologous proteins. As an example, we chose E7, based on
its strong differential seroreactivity between cancer and asymptom-
atic patients, and since E7 is continuously expressed in HPV-
associated cancers. Fig. S3 documents that while 55% of all samples
showed reaction against any HPV E7 protein, only 24%, 10%, 5%, and 1%
of all samples reacted with two or more, three or more, four or more,
or ﬁve or more different E7 proteins. We conclude that for proteins
with limited sequence identity such as E7, there is only a moderate
bias due to serological cross-reactions.
We also sought to identify a set of antigens able to accurately
distinguish HPV-infected patients from healthy subjects. As such, we
studied the discriminatory power of different sets of antigens using
receiver operating characteristic (ROC) curves. We used kernel
methods and support vector machines to build linear and nonlinear
classiﬁers. Table 1 shows the top 14 antigens that best discriminate
between cancer and asymptomatic subjects. Thirteen of the top 14
discriminatory antigens were early gene products from ‘high-risk’
HPV types.
Discussion
Automated microdeposition technologies have become powerful
tools for molecular studies as they allow screening high-density
protein arrays for enzyme–substrate, DNA–protein and protein–
protein interactions and are ideally suited for comprehensive
investigation of humoral immune responses to infections due to
their high-throughput format and miniaturization. Protein micro-
arrays can be used to interrogate the entire proteome of infectious
microorganisms consisting of hundreds to thousands of potential
antigens while consuming only small quantities of individual sera (a
few microliters of sera per patient). This approach permits investi-
gators to perform large-scale sero-epidemiological, longitudinal, and
sero-surveillance analyses and immunoreactive responses at various
stages of the infectious process in a manner not possible with other
technologies.
Protein microarray technologies have limitations, however, be-
cause protein puriﬁcation in combination with high-throughput gene
expression systems is difﬁcult. One problem is the complexity of
protein folding and posttranslational modiﬁcation, which is difﬁcult
to recreate on a microarray platform. On the other hand, standard
criteria for array production and data normalization with noise
models, variance estimation, and differential expression analysis
techniques have become powerful for the interpretation of results.Based on this progress, successful attempts have been made using
protein microarrays for proﬁling the humoral immune response to
numerous infectious agents (Barbour et al., 2008; Davies et al., 2005a,
b, 2008; Doolan et al., 2008; Felgner et al., 2009; Sundaresh et al.,
2006).
Our study demonstrates the power of a microarray-based
approach to scan the humoral immune responses against antigens
of the most prevalent HPV types. Our data conﬁrm generalizations
that emerged from previous studies of individual or few HPV proteins,
namely unsystematic seroresponses to HPV-associated lesions and in
the absence of symptoms. Apparently, long-term expression of HPV
Table 1
Individual p values comparing the seroresponse against listed individual HPV early proteins in the comparison of individuals with cancer, high- and low-grade lesions, and
asymptomatic smears. Signiﬁcantly differentially reactive E proteins (pb0.05) are highlighted with bold fonts. The antigens are ranked by p value for discriminating individuals with
cancer (column 2).
Comparison (number of patients) No lesions
(280) vs.
cancer (93)
Low-grade lesions
(LSIL) (123) vs.
cancer (93)
High-grade lesions
(HSIL) (50) vs.
cancer (93)
No lesions (280) vs.
low-grade lesions
(LSIL) (123)
No lesions (280) vs.
High-grade lesions
(HSIL) (50)
Low-grade lesions (LSIL)
(123) VS High-grade
lesions (HSIL) (50)
HPV-31 E7 5.87E−09 3.87E−05 0.0500 0.3900 0.7441 0.9359
HPV-18 E7 7.33E−08 0.0003 0.3283 0.5208 0.3101 0.9359
HPV-33 E6 0.0037 0.0417 0.3045 0.4123 0.4606 0.9359
HPV-35 E7 0.0040 0.0228 0.3796 0.9866 0.7929 0.9359
HPV-16 E7 0.0052 0.0050 0.3045 0.3900 0.1890 0.9359
HPV-16 E6 0.0055 0.2773 0.4246 0.3845 0.5425 0.9862
HPV-16 E1 0.0077 0.1926 0.8683 0.3845 0.3101 0.9359
HPV-11 E1 0.0139 0.4976 0.4427 0.1939 0.6589 0.9359
HPV-33 E7 0.0171 0.0050 0.3045 0.7503 0.9685 0.9359
HPV-33 E5 0.0174 0.0417 0.1198 0.8140 0.9646 0.9862
HPV-53 E1 0.0176 0.0968 0.6998 0.8140 0.5425 0.9359
HPV-31 E1 0.0212 0.3483 0.8561 0.4123 0.4456 0.9970
HPV-33 E1 0.0275 0.5247 0.8529 0.5208 0.4817 0.9862
HPV-16 E4 0.0280 0.2272 0.5426 0.8140 0.8443 0.9640
Number of differentially reactive E proteins 14 7 1 0 0 0
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necessarily lead to a strong antibody response against all HPV proteins
that are expressed at some stage of the infectious process. This lack of
consistent humoral immune response even applies to the E7 protein
whose continued expression is a molecular hallmark of HPV-
associated cancers. However, our research identiﬁed antibodies
against E7 proteins (but not against the second oncoprotein E6), as
the most prominent response in cancer patients, as our analyses
conﬁrmed E7 as the most consistent differentially reactive antigen,
when sera from cancer patients were compared with those of
asymptomatic subjects. Our research has to be compared with—and
largely conﬁrms—previous studies of anti-HPV seroresponses in
cervical cancer and control patients (DiBonito et al., 2006; Lehtinen
et al., 2003; Meschede et al., 1998; Reuschenbach et al, 2009; Smith et
al., 2007; Suchánková et al, 1991; Viscidi et al, 1993; Waterboer et al.,
2005). These publications reported immune responses against E6, E7,
and L1 as more frequent in patients with invasive cancer than in
asymptomatic controls based on enzyme-linked immunosorbent
assays (ELISAs) of individual or few HPV proteins. Only one of these
studies developed a multiplex approach with glutathione S-transfer-
ase fusion E6 proteins (Waterboer et al., 2005) of HPV-16, -18, -52,
and -58.
In our analysis of cancer patients, we detected anti-E7 and E1
antibodies most frequently. While signiﬁcant, these values are stillFig. 6. Anti-E7 immune responses exist only in a subset of cancer patients, whose HPV type
patients does not mean that the presence of this antigen in all patients induces consistentlsuboptimal for clinical diagnosis. While measurements of anti-E7
immune responses are at this point not useful as a primary diagnosis
to detect HPV-associated cancer, they nevertheless raise the issue of
medical applications of this ﬁnding. Could monitoring of anti-E7
immune response become more useful in the context of cellular
tumor speciﬁc antigens? Does anti-E7 seroreactivity deﬁne a subset of
cervical cancers with a unique treatment proﬁle? Do anti-E7
antibodies affect HPV-associated tumors, and if yes, would this notion
support the case for therapeutic vaccination?
Unfortunately, in contrast to the differences between cancer and
asymptomatic patients, we could not conﬁrm anti-E7 seroresponses
as useful biomarkers of early progression, as the differences between
asymptomatic subjects and patients with precursor lesions were not
signiﬁcant. This is disappointing as serology often has the power to
detect latent viral and bacterial infections such as those leading to
AIDS and syphilis. A large and long-term prospective Scandinavian
study has come to the same conclusion as our research, namely that
anti-HPV oncoprotein seropositivity is not induced before invasion
andmay not be a powerful early diagnostic marker ormarker of occult
disease (Lehtinen et al., 2003; Stanley, 2003) nor did the presence of
antibodies associate signiﬁcantly with disease prognosis (Silins et al.,
2002).
Antibodies against L1 proteins, of central interest in the era of anti-
HPV vaccination, were not detected as frequently as those againststatus was known. The data document that the preferential reactivity of E7 in cancer
y an anti-E7 immune response.
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whether potentially inappropriate folding of L1 affected this part of
our data set. However, while anti-L1 immune responses clearly
identify HPV-infected patients, it was not discriminatory of cancers.
Thismay be because L1 proteins are often not produced in cancers due
to interruption of the HPV genomes. However, ELISA assays using
VLPs indicate the prevalence of antibodies against L1 may be higher
than we ﬁnd here (for example, Jeong et al, 2009; Wang et al, 2004)
which is likely owing to the native conﬁguration of the L1 presented
by the VLP.
Our approach can obviously be used to address many questions
that we did not yet address. For example, microarrays could be
powerful to better understand the humoral immune response against
those HPVs speciﬁcally infecting the skin. Our microarrays included
HPV-1, -2, -4, and -5, four remotely related HPV types that are
normally found in lesions of the skin. Previous serological studies
indicate that infections with cutaneous HPVs are much more frequent
than reﬂected by the relatively rare occurrence of skin lesions
(Boxman et al., 1999; Steger et al., 1990; Waterboer et al., 2009).
Data included in the ﬁgures, but not explicitly discussed, showed
relatively frequent immune responses only against some few proteins
of these types, notably HPV-2 E1, HPV-2 E4, HPV-4 L2, HPV-5 E5, and
HPV-5 L2. Additional studies could be used to gain a more detailed
understanding of the serology of these and other cutaneous HPV
types.
Materials and methods
Cloning of HPV genes
The genome clones of HPV types 1, 2, 4, 5, 6, 11, 16, 18, 31, 33, 35,
45, and 53 have been maintained in our (M.K., H.U.B.) laboratories for
more than 20 years and were originally received from the reference
center for human papillomaviruses at the German Cancer Research
Center, Heidelberg. DNA segments with all the speciﬁc open reading
frames were generated based on GenBank entries and with reference
to the original compilation of the HPV sequence database (Baker and
Calef, 1995; Myers et al., 1994). We isolated the open reading frames
E6, E7, E1, E2, E4, E5, L2, and L1 of each HPV type listed above in the
form of PCR amplicons with primer pairs that corresponded to the
ﬁrst and last 20 nucleotides of each gene. The primer 5′-
CATATCGACGACGACGACAAGCATATGCTCGAGN5′–20-3′ contained the
ﬁrst 20 nucleotides of each HPV gene (coded N5′–20), and the primer
5′-N3′–20ATCTTAAGCGTAATCCGGAACATCGTATGGGTA-3′ the last 20
nucleotides of the respective gene (N3′–20). The listed nucleotides
sequences are complementary to those used for vector linearization
(see following paragraph) and are targets of homologous recombi-
nation between HPV amplicons and the vector. In 50-µl PCR reactions,
we used 0.02 U/µl Taq DNA polymerase (buffer A, Fisher Scientiﬁc),
0.1 mg/ml gelatin (Bloom300, Porcine; G-1890, Sigma), and a 0.2 mM
concentration of each dNTP. Conditions were as follows: Initial
denaturation of 95 °C for 5 min; 30 cycles of 20 sec at 95 °C, 30 sec
at 50 °C, and 60 sec/kb at 72 °C. The PCR product was visualized by
agarose gel electrophoresis of 3 µl of the reaction mix.
PCR ampliﬁcation of the acceptor vector
The details of this protocol have been published (Davies et al.,
2005a,b). Linear acceptor vector was generated by PCR amplifying
30 pg plasmid pXT7-DESTwith the Expand Long Template PCR system
buffer 1 (Roche, Switzerland) containing 0.2 mM dNTPs and 0.8 U Taq
polymerase and the two primers (0.5 µM each): 5′-TACCCATAC-
GATGTTCCGGATTAC-3′ (facing from the end of the linear PCR product
toward the T7 promoter and recipient of the 5′ end of the HPV insert)
and 5′-CTCGAGCATATGCTTGTCGTCGTCG-3′ (recipient of the 3′ end of
the HPV insert) with the following conditions: initial denaturation of94 °C for 5 min, followed by a 35 fold repetition of 95 °C for 30 sec,
50 °C for 30 sec, and 68 °C for 3 min, and a ﬁnal extension at 68 °C for
10 min.
In vivo recombination cloning method
About 10 µl of competent E. coli DH-alpha was transformed with
40 ng of PCR-generated linear vector and 10 ng of PCR-generated gene
fragment (molar ratio approximately 1:1) following the typical
temperature shift and growth steps. Prior puriﬁcation of the PCR
products was not necessary. The transformed E. coli preparations were
grown overnight in LB medium under kanamycin selection. Plasmid
isolation and puriﬁcation from these cultures did not require prior
colony selection as described (Davies et al., 2005a,b).
HPV protein expression and microarray chip printing
Plasmid templates for in vitro transcription/translation were
prepared by using QIAprep Spin Miniprep kits (Qiagen, Venlo,
Netherlands). In vitro transcription/translation reactions (RTS 100
Escherichia coli HY kits; Roche, Switzerland)were set up in 0.2-ml PCR
12-well strip tubes and incubated for 5 h at 30 °C, according to the
manufacturer's instruction. For microarrays, 32.5 µl of 0.2% Tween-20
was mixed with 100 µl of RTS reaction (to a ﬁnal concentration of
0.05% Tween-20), and 15 µl volumes were transferred to 384-well
plates for printing. The plateswere centrifuged at 1600×g to pellet any
precipitate, and the supernatant was printed without further puriﬁ-
cation onto NC coated FAST glass slides (Schleicher and Schuell
Bioscience, Keen, NH, USA) with an OmniGrid 100 microarray printer
(Genomic Solutions, Ann Arbor, MI, USA). The proteins from all genes
were spotted in duplicate, and all data valueswere used as the average
of pairs. In addition, each chip contained an area printed with controls
consisting of RTS reaction without template DNA or with an empty T7
vector control. Expression of complete proteins was monitored with
monoclonal anti-polyhistidine (clone His-1, Sigma-Aldrich, St. Louis,
USA) and anti-hemagglutinin (clone 3F10; Roche, Switzerland).
Antibody assays and reading of microarrays
Before array probing, sera were diluted to 1:100 in Protein Array
Blocking Buffer (Whatman, GE Healthcare) containing E. coli lysate at a
ﬁnal concentration of 10 mg/ml and incubated at room temperature for
1 h with constant mixing. The arrays were rehydrated and blocked in
blocking buffer for 30 min and then probedwith the pretreated sera for
24 h at4 °Cwith constant agitation. The slideswerewashedﬁve times in
10 mM Tris (pH 8.0)–150 mM NaCl containing 0.05% Tween 20 buffer,
and bound human antibodieswere detected by1 h incubation in Biotin-
sp conjugated Afﬁni Pure Goat anti-human IgG Fc (Fc-γ fragment
speciﬁc) secondary antibody (Jackson Immunoresearch, West Grove,
PA) diluted 1:1000 in blocking buffer. The slides were washed three
times in 10 mM Tris buffer (pH 8.0)–150 mM NaCl containing 0.05%
Tween 20. Bound antibodies were detected by 1 h of incubation with
streptavidin-conjugated SureLight® P-3 tertiary reagent (Columbia
Biosciences, Columbia,MD)diluted 1:200 in blocking buffer. After being
washed ﬁve times, the slides were air-dried under brief centrifugation
and stored at 18 °C in a desiccator. The arrays were examined with a
Perkin Elmer ScanArray Express HT confocal laser scanner at a
wavelength of 670 nm, and intensities were quantiﬁed using ProSca-
nArray Express software (Perkin Elmer, Waltham, MA). All signal
intensities were corrected for spot-speciﬁc background.
Origin of clinical samples
All sera for this project came from three archival collections, i.e.,
they were aliquots of samples that had been collected for other
research than our study. Altogether, 546 samples entered this project.
39M. Luevano et al. / Virology 405 (2010) 31–40Among these, 427 samples were obtained from patients treated in
Monterrey, Mexico, between the years 2002 and 2008. Among these
samples from Monterrey, 280 subjects did not contain any detectable
cervical lesions. From these asymptomatic individuals, we obtained
smears that were presently HPV-positive and negative as judged by
DNA testing. HPV status in these asymptomatic patients did not enter
this study as a separate variable, as pilot data did not show any
serological differences between the two groups. Ninety-four patients
fromMonterrey had low-grade (LSIL) and 39 patients had high-grade
squamous intraepithelial lesions (HSIL); 13 patients had squamous
cervical carcinomas and 1 patient had an adenocarcinoma. Sera of 61
patients with squamous cell carcinomas and 18 with adenocarcino-
mas were obtained from Mexico City, Mexico. Squamous cell
carcinomas and adenocarcinomas were treated as one category in
this study. The sera from 29 patients with LSIL and 11 patients with
HSIL were obtained from Sao Paulo, Brazil. As a control for patients
without a history of sexual activity, we used 10 sera of 2- to 3-year-old
children from Kenya that had been sampled during a malaria-related
research (Doolan et al., 2008). The original studies had been done
with permission of the respective institutional review boards (IRBs).
For our research, the IRB of the University of California Irvine classiﬁed
this project as exempt because all our samples were archival and did
not contain any patient identiﬁers.Monoclonal antibodies
The following 12monoclonal antibodieswere used: fromSanta Cruz
Biotechnology, Inc., SantaCruz, California:HPV16E6 (SC-1583);HPV-16
E7 (SC-264); HPV-16 E7 (SC-6981); HPV-16 E1/E4 (SC-53324); HPV-
16 L2 (SC-65708); HPV-18 E7 (SC-51954); HPV-18 E2 (SC-26938);
HPV-11 E7 (SC-66145); from Chemicon, Temecula, California: HPV-
18,16 E6 (MAB874); HPV-16 E2 (MAB8678); HPV-16 E2 (MAB8679);
HPV-16 L1 (MAB885).Data analysis
Data were analyzed with the R (http://www.r-project.org) and
SAS (http://www.sas.com/) statistical software. Previous literature
has shown that data derived from microarray platforms are
heteroskedatic (Baldi and Hatﬁeld, 2002; Sundaresh et al., 2006,
2007). To stabilize the variance (Durbin et al., 2002; Huber et al.,
2002), the vsn normalization method implemented as part of the
Bioconductor suite (www.bioconductor.org) is applied to the
quantiﬁed array intensities. In addition to removing heteroskedas-
ticity, this procedure corrects for nonspeciﬁc noise effects by
ﬁnding maximum likelihood shifting and scaling parameters for
each array such that control probe variance is minimized. This
calibration has been shown to be effective on a number of
platforms (Kreil et al., 2004).
Differentially reactive proteins between groups were deter-
mined using a Bayes regularized t-test adapted from Cyber-T for
protein arrays (Baldi and Hatﬁeld, 2002; Baldi and Long, 2001),
which has been shown to be more effective than other differential
expression techniques (Long et al., 2001). To account for multiple
comparison conditions, the Benjamini and Hochberg (BH) method
was used to control the false discovery rate (Benjamini and
Hochberg, 1995). After Benjamini and Hochberg correction, p
values smaller than 0.05 are considered signiﬁcant, and the
corresponding protein is considered differentially reactive. Multi-
plex classiﬁers were constructed using linear and nonlinear support
vector machines (SVMs) using the “e1071” R package. Plots of
receiver operating characteristic (ROC) curves were made with the
‘ROCR” R package. Sensitivity and speciﬁcity were determined from
the resulting ROC curves.Acknowledgments
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